Login to Your Account



MacuClear Sets Sights on AMD, Starts Phase III Trial of MC-1101

By Marie Powers
Staff Writer

Thursday, April 12, 2012
MacuClear Inc. has tossed its hat into the age-related macular degeneration (AMD) ring with the first of two pivotal Phase III studies for lead compound MC-1101. The topically administered drug, delivered as an eye drop, is designed to treat and stop the progression of AMD from early stage, or the dry form, to late-stage, or wet AMD, by increasing ocular blood flow in the choroidal vessels.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription